ArticleScience immunology2025
Dynamic STING repression orchestrates immune cell development and function.
Abstract read
In one paragraph
Article in Science immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Metabolic stress-activated endothelial STING rewires the sinusoidal immune niche to promote MASLD progression.The Journal of clinical investigation · 2026Article
- Spatiotemporal control of STING activation and saRNA delivery decouples humoral and cellular immunity.bioRxiv : the preprint server for biology · 2026Article
- Dual Covalent Targeting of STING Cysteines 292/309 Disrupts Functional Oligomerization and Enables Potent Antagonist Development.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Nanotechnology-driven STING regulation for on-demand therapy.Acta pharmaceutica Sinica. B · 2026Review
- Characterization of a novel cell wall-associated nucleotidase of Enterococcus faecalis that degrades extracellular c-di-AMP.PLoS pathogens · 2026Article
- STING synergizes with TOX suppressing HO-1 expression to trigger ferroptosis in tumor-infiltrating CD8+ T cell and immunotherapy resistance.Nature communications · 2026Article
- STING signaling pathway: An oasis in the glioblastoma immune desert.Theranostics · 2026Review
- Targeting STING Signalling Polarizes Tumor-Associated Neutrophils to Boost Anticancer and Abscopal Antimetastatic Functions.ImmunoTargets and therapy · 2026Article
- STING Restricts EV-A71 Infection by Regulating T Cell Development and Enhancing Immune Cell Effector Function.International journal of molecular sciences · 2025Article
- Autonomous STING signaling in Purkinje cells drives neurodegeneration independent of type I interferon.Cell reports · 2025Article
- Matrix mechanical remodeled carrier-free nanosystem for programmable closed-loop reversal of liver fibrosis via STING alkylation.Science advances · 2025Article
- Breaking barriers: The cGAS-STING pathway as a novel frontier in cancer immunotherapy.Cancer communications (London, England) · 2025Review
- Improvement of the Anticancer Efficacy of PD-1/PD-L1 Blockade: Advances in Molecular Mechanisms and Therapeutic Strategies.MedComm · 2025Review
- Loss of stimulator of interferon genes (STING) promotes accumulation of cholesterol and triglycerides throughout life in mice.Biological research · 2025Article
- Response to two Janus kinase inhibitors in a boy with SAVI during 2-year follow-up: case report and literature review.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Kennady KnoxDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0003-3874-1691
Devon JeltemaDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-5338-3477
Nicole DobbsDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0003-1944-9740
Kun YangDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-2011-7084
Cong XingDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0001-9641-335X
Kun SongDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Zhen TangDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Gustavo Torres-RamirezDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0009-0006-7917-8961
Jiefu WangDepartment of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin 300060, China.ORCID 0000-0001-6164-342X
Shan GaoDepartment of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin 300060, China.
Tuoqi WuDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-4003-1034
Chen YaoDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0001-6852-5661
Jian WangDepartment of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin 300060, China.ORCID 0000-0002-9286-2809
Nan YanDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-0637-3989
Funding
UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Kathryn Ann O'Donnell · 2010 to 2026
$53.7MINTEGRATIVE IMMUNOLOGY TRAINING PROGRAMT32AI005284 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI Nan Yan · 2003 to 2026
$7.4MMechanism of STING-mediated Neuropathology in Niemann-Pick DiseaseR01NS122825 · NINDS · UT SOUTHWESTERN MEDICAL CENTER · PI YAN, NAN · 2021 to 2025
$2.4MThe Mitochondrion-STING Axis in An Early Childhood Onset Neurodegenerative DiseaseR01NS117424 · NINDS · UT SOUTHWESTERN MEDICAL CENTER · PI YAN, NAN · 2021 to 2025
$2.3MSting Trafficking and Signaling Beyond InterferonR01AI151708 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI YAN, NAN · 2020 to 2023
$2.1MSTING Trafficking, Activation and Signaling Beyond InterferonR56AI134877 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI YAN, NAN · 2018 to 2018
$405kSTING Signaling in Health and DiseaseR56AI151708 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI YAN, NAN · 2024 to 2024
$339kNCI NIH HHS P30 CA142543NIAID NIH HHS R01 AI151708NIAID NIH HHS R56 AI134877NIAID NIH HHS R56 AI151708NIAID NIH HHS T32 AI005284NINDS NIH HHS R01 NS117424NINDS NIH HHS R01 NS122825
Abstract
STING is an essential component of the innate immune system, yet homeostatic STING expression patterns and regulation are unknown. Using
Indexed as
CD8-Positive T-LymphocytesMembrane ProteinsAnimalsColorectal NeoplasmsHumansImmunity, InnateMiceMice, Inbred C57BLMice, TransgenicNeutrophilsSTING ProteinTumor MicroenvironmentMembrane ProteinsSting1 protein, mouseSTING Protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.